Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is N/A as of Tuesday, October 6, 2026.
GROSS MARGIN
N/A
Market Cap
$225.24M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$231.37M
Gross Margin
71.12%
TTM Avg
81.41%
3Y Avg
85.88%
5Y Avg
90.00%
Market Cap
$231.77M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$232.72M
Gross Margin
-24677.94%
TTM Avg
-13289.35%
3Y Avg
-6830.59%
5Y Avg
-4553.73%
Market Cap
$220.93M
Gross Margin
71.79%
TTM Avg
68.33%
3Y Avg
60.69%
5Y Avg
55.54%
Market Cap
$235.08M
Gross Margin
54.88%
TTM Avg
55.31%
3Y Avg
58.01%
5Y Avg
59.27%
Market Cap
$235.66M
Gross Margin
79.48%
TTM Avg
71.93%
3Y Avg
74.52%
5Y Avg
72.98%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vogenx Inc. (VOGX) | $227.91M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | 82.50% | 79.64% | 73.94% | 65.24% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | 0.00% | 0.00% | 0.00% | 0.00% |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | 71.12% | 81.41% | 85.88% | 90.00% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | 0.00% | 0.00% | 0.00% | 0.00% |
| InflaRx N.V. (IFRX)vs › | $232.72M | -24677.94% | -13289.35% | -6830.59% | -4553.73% |
| Profound Medical Corp. (PROF)vs › | $220.93M | 71.79% | 68.33% | 60.69% | 55.54% |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 54.88% | 55.31% | 58.01% | 59.27% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | 79.48% | 71.93% | 74.52% | 72.98% |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | 68.57% | 73.00% | 80.96% | 81.80% |
Gross Margin
N/A
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
